Group items tagged

For patients with acute coronary syndromes (ACS), diabetes mellitus (DM), but not pre-DM, is associated with an increased risk of major adverse cardiac events (MACE), according to a study published online Oct. 18 in the Journal of the American College of Cardiology. Serdar Farhan, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined the impact of pre-DM on coronary plaque characteristics and ischemic outcome in patients with ACS. Participants underwent quantitative coronary angiography, grayscale intravascular ultrasound (IVUS), and radiofrequency IVUS after successful percutaneous coronary intervention. Patients were categorized based on their glucometabolic status as normal glucose metabolism (NGM; 162 patients), pre-DM (202 patients), and DM (183 patients). The researchers found that there were no significant between-group differences with respect to IVUS findings indicative of vulnerable plaques. Compared to patients with pre-DM or NGM, patients with DM had a higher crude rate of MACE (25.9 versus 16.3 and 16.1 percent; P = 0.03 and 0.02, respectively). Using NGM as the reference group, DM, but not pre-DM, was correlated with increased risk of MACE in an adjusted model (hazard ratios, 2.2 [95 percent confidence interval, 1.25 to 3.86; P = 0.006] and 1.29 [95 percent confidence interval, 0.71 to 2.33; P = 0.41]).

Transcatheter Cardiovascular Therapeutics (TCT) is organized by CardioVascular Research Foundation (CRF) and would be held during Oct 29 - Nov 2, 2017 at Colorado Convention Center, Denver, Colorado, United States of America. The target audience for this medical event for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine. Activity Goals : The overall goal of this activity is to improve the competence and performance of our target audience by delivering cutting-edge educational content that showcases the latest advances in current therapies and clinical research. We hope that our longstanding commitment to lifesaving innovation will translate into improved patient care. Learning Objectives : By the end of the symposium, participants should be able to: * Apply the results from important clinical trials and evidence-based medicine to guide the management of patients with atherosclerosis and structural heart disease * Incorporate new interventional technologies and procedures into the care of patients with complex coronary and endovascular disease * Integrate advances in diagnostic evaluation and therapeutics into the treatment of patients with carotid and peripheral arterial disease * Implement appropriate pharmacologic management in the care of patients undergoing diagnostic arteriography and interventional therapies before, during, and after catheterization * Identify new interventional technologies and propose appropriate applications for patients with cardiovascular disease

Transcatheter Cardiovascular Therapeutics (TCT) is organized by CardioVascular Research Foundation (CRF) and would be held during Oct 29 - Nov 02, 2017 at Colorado Convention Center, Denver, Colorado, United States of America. The target audience for this medical event for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine. Activity Goals : The overall goal of this activity is to improve the competence and performance of our target audience by delivering cutting-edge educational content that showcases the latest advances in current therapies and clinical research. We hope that our longstanding commitment to lifesaving innovation will translate into improved patient care. Learning Objectives : By the end of the symposium, participants should be able to: * Apply the results from important clinical trials and evidence-based medicine to guide the management of patients with atherosclerosis and structural heart disease * Incorporate new interventional technologies and procedures into the care of patients with complex coronary and endovascular disease * Integrate advances in diagnostic evaluation and therapeutics into the treatment of patients with carotid and peripheral arterial disease * Implement appropriate pharmacologic management in the care of patients undergoing diagnostic arteriography and interventional therapies before, during, and after catheterization * Identify new interventional technologies and propose appropriate applications for patients with cardiovascular disease